Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1 [0.03%]
派泊利单抗诱导的难治性霍奇金淋巴瘤患者复发时出现自身免疫溶血性贫血
Yiming Tao,Jie Han,Yongsheng Li
Yiming Tao
In August 2021, penpulimab, an anti-programmed cell death 1 (PD-1) monoclonal antibody, was approved in China for the treatment of adult patients with relapsed or refractory classic Hodgkin's lymphoma who completed at least second-line chem...
Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia [0.03%]
出口蛋白1在成人T细胞白血病增殖和存活中起关键作用
Chie Ishikawa,Naoki Mori
Chie Ishikawa
Since treatment options for adult T cell leukemia (ATL) associated with human T cell leukemia virus type 1 (HTLV-1) fail to obtain long-term response, novel therapies targeting ATL-dysregulated pathways are necessary. Dysregulated nuclear i...
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells [0.03%]
NSC305787，一种药用的ezrin抑制剂，在胰腺癌细胞中具有抗肿瘤活性
Jean Carlos Lipreri da Silva,Maria Fernanda Lopes Carvalho,Livia Bassani Lins de Miranda et al.
Jean Carlos Lipreri da Silva et al.
Pancreatic cancer is one of the most lethal human neoplasms, and despite advances in the understanding of the molecular complexity involved in the development and progression of this disease, little of this new information has been translat...
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience [0.03%]
仑伐替尼联合纳武单抗治疗晚期肝细胞癌的回顾性分析
Wen-Chi Wu,Tzu-Yuan Lin,Ming-Huang Chen et al.
Wen-Chi Wu et al.
Lenvatinib, a multi-tyrosine kinase inhibitor that inhibits vascular endothelial growth factor and fibroblast growth factor receptors pathway, activated the immune response in tumor microenvironment. However, the combination of lenvatinib a...
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study [0.03%]
艾伏泽宁单药治疗经治的晚期实体瘤患者：一项首次人体I期临床试验的结果
Patricia LoRusso,Mark J Ratain,Toshihiko Doi et al.
Patricia LoRusso et al.
Eftozanermin alfa (eftoza), a second-generation tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist, induces apoptosis in tumor cells by activation of death receptors 4/5. This phase 1 dose-escalation/dose-opt...
A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report [0.03%]
一例CTNND1-ALK融合阳性肺腺癌患者的阿来替尼敏感病例报告
Xiang Tian,Qiong Liao,Qidong Yang et al.
Xiang Tian et al.
Genomic fusions of anaplastic lymphoma kinase (ALK) are a well-established therapeutic target in non-small-cell lung cancer (NSCLC). Although various ALK fusion variants have been identified in NSCLC, their responses to ALK tyrosine-kinase ...
Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells [0.03%]
纳武单抗和伊匹单抗对顺铂耐药的小细胞肺癌细胞的抑制作用
Wei Chi,Lianyong Zhang,Xue Wang et al.
Wei Chi et al.
Background: Small cell lung cancer (SCLC) accounts for nearly 10-15% of all lung cancer cases. Although many chemotherapy drugs, such as cisplatin and etoposide, were approved as primary therapy for SCLC patients, the pro...
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis [0.03%]
间变性淋巴瘤激酶阳性的非小细胞肺癌患者酪氨酸激酶抑制剂毒性特征的系统评价和 meta 分析
Yunxia Tao,Yu Zhou,Le Tang et al.
Yunxia Tao et al.
Anaplastic lymphoma kinase (ALK) inhibitors are commonly used for patients harboring ALK-positive non-small cell lung cancer (NSCLC). This meta-analysis was conducted to evaluate the toxicity profile of ALK inhibitors. Pubmed, Web of Scienc...
Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects [0.03%]
利福平对健康志愿者中抗肿瘤药物马来雷迪帕韦片药代动力学的影响研究
Ming-Min Cai,Ting Dou,Lu Tang et al.
Ming-Min Cai et al.
Purpose: Pyrotinib (PTN), an irreversible EGFR/HER2 dual tyrosine kinase inhibitor used for treating HER2-positive breast cancer, is primarily metabolized by cytochrome P450 (CYP)3A4 isozyme. Rifampicin (RIF) is a strong ...
Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients [0.03%]
由糖酵解免疫相关基因构建的标志物可预测骨肉瘤患者的预后
Kangsong Tian,Wei Qi,Qian Yan et al.
Kangsong Tian et al.
Background: Glycolysis and tumor immunity were interrelated. In present study, we aimed to construct a prognostic model based on glycolysis-immune-related genes (GIGs) of osteosarcoma (OS) patients. ...